RHOADS ANN D

Director Ann D. Rhoads buys 750 QDEL shares at $28.28; stock -39.5% from 52-week high amid -7.2% revenue decline and $-733.0M annual loss.

Ann D. Rhoads, a director at QuidelOrtho, purchased 750 shares at $28.28 on 2025-12-10, increasing her holdings by 5.3% to 15,021 shares. The purchase occurs within a challenging fundamental backdrop: the company reported annual revenue decline of -7.2%, full-year net income of $-733.0M, and the stock is trading -39.5% below its 52-week high of $47.61. The 30-day price momentum (+46.0%) shows recent recovery, but the 90-day change remains negative at -3.8%. Across her broader trading history spanning multiple tickers, Rhoads' previous sales have not demonstrated consistent timing accuracy (90d well-timed rate 0.00%), suggesting this purchase should be evaluated on its standalone merits rather than as a signal of demonstrated predictive acumen specific to this company.

Director Ann D Rhoads sold 15,000 shares of GMED at $70.36 on 2024-09-13; retains 42,884 shares post-transaction.

Director Ann D Rhoads sold 15,000 shares (representing -25.9% of her pre-transaction holdings) at $70.36, generating $1,055,400.00 in proceeds. The sale occurred when GMED was trading near its 52-week high of $73.92, within 1.6% of that peak. GMED exhibits strong fundamentals with annual revenue growth of +53.3% and a market cap of $9,389,122,558.78, though the P/E of 231.13 reflects substantial valuation premium. The directional signal is mixed: the sale timing (near 52-week highs) could suggest opportunistic execution, yet Rhoads retains 42,884 shares, maintaining a substantial position in the company. The magnitude of this reduction—roughly one-quarter of holdings—warrants monitoring for context about motivation, but the available facts do not establish whether this reflects portfolio rebalancing, liquidity needs, or other factors.